Umbo CV (盾心科技), an artificial intelligence (AI) start-up that provides recognition systems used in cameras for professional security firms, yesterday announced that it has completed a round of US$2.8 million seed funding led by AppWorks Ventures (之初創投).
The investors include Wistron Corp (緯創), Phison Electronics Corp (群聯電子), Mesh Ventures and Fortune Global 500, according to a press statement distributed by Marketwired.
“This funding gives us the financial strength to advance our goals of developing automated event recognition systems that are capable of spotting anomalies from security cameras, leading real-time protection of people and their assets with less human capital,” Umbo CV chief executive officer Shawn Guan (關宇翔) said in the statement.
The company said it will leverage the funds to expand its research and development, marketing and sales units in support of the launch of its first product — a self-learning cloud camera, Umbo SmartDome — along with its management platform.
Umbo SmartDome is to be launched at the International Security Conference and Exposition in Las Vegas, Nevada, and begin shipping worldwide next month, with the first few shipments to fulfill the US$1.4 million pre-orders placed from North America, Australia and Dubai, the statement said.
The company also plans to recruit more staff for its offices in San Francisco and Taipei this year, it said.
AppWorks co-founder Jamie Lin (林之晨) said Umbo CV is clearly in line with trends in the security industry for AI to meet traditional surveillance practices.
Wistron said that it sees great potential in Umbo CV’s technologies in the security industry, adding that Wistron also has similar technologies it could share with Umbo CV.
“We believe that artificial-intelligence cameras capable of deep learning and computing have great potential,” an official at Wistron said, declining to disclose the amount of its investment.
While Umbo CV is still at the early stages, Wistron does not rule out boosting its cooperation with Umbo CV, the company said.
JPMorgan Chase & Co chief executive officer Jamie Dimon on Tuesday quipped that his company is likely to outlast the Chinese Communist Party (CCP), while reiterating the bank’s commitment to the country in wide-ranging comments that also touched on Taiwan, free speech and former US president Donald Trump. “We hope to be there [in China] for a long time,” Dimon told a panel discussion at the Boston College Chief Executives Club. Relaying a “joke” he made during a recent visit to Hong Kong, he said “The communist party is celebrating its 100th year. So is JPMorgan. And I’ll make you a
The Kaohsiung City Government yesterday said it would impose a property hoarding tax as it is seeking to contain speculation in the real-estate market, calling recent price increases “abnormal.” The announcement came in support of the Ministry of Finance’s call for local governments to levy a high tax rate on people with more than one property. Ministry officials on Tuesday discussed strategies to rein in speculation with the nation’s six special municipalities, as well as the Hsinchu city and county governments. About 84,000 out of 1.06 million housing units in Kaohsiung are not residential property, the city government said in a
BOOST EXPECTED: Higher market prices would offset effects of the industry’s transition to more climate-friendly production methods, a company official said China Steel Corp (CSC, 中鋼) expects steel demand to increase on the back of governments around the world subsidizing infrastructure construction amid a stabilizing COVID-19 pandemic, CSC chairman Wong Chao-tung (翁朝棟) told an investors’ meeting yesterday. “After getting through the hard times, I foresee at least one year, very possibly two years, of strong steel market,” Wong said. Calling a dip in steel prices a “short respite for the market,” Wong said that it would likely bounce back early next year on the back of mild winter temperatures around the world allowing construction activity. Despite COVID-19 spikes in some regions and increased
PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12. Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12. PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack. PharmaEssentia is preparing to make Besremi available in the US in the